Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Adia MedADIA +15.54%20 Days Sales Outstanding is 46.28 as of Jun. 2026, which is 169% above its 10-year median of 17.18. GuruFocus rates ADIA with a GF Score™ of 20/100. The stock has 5 warning signs investors should review. Among 664 Healthcare Providers & Services companies, Adia Med ranks better than 84.19% on this metric.
Adia Med's average Accounts Receivable for the
six
months ended in Jun. 2026 was $0.06 Mil. Adia Med's Revenue for the
six
months ended in Jun. 2026 was $0.49 Mil.
Hence, Adia Med's Days Sales Outstanding for the
six
months ended in Jun. 2026 was 23.14.
The historical rank and industry rank for Adia Med's Days Sales Outstanding or its related term are showing as below:
ADIA'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 17.18 Med: 17.18 Max: 17.71
Current: 17.71
During the past 2 years, Adia Med's highest Days Sales Outstanding was 17.71. The lowest was 17.18. And the median was 17.18.
ADIA's Days Sales Outstanding is ranked better than 84.19% of 664
companies
in the Healthcare Providers & Services industry
Industry Median: 45.78
vs ADIA: 17.71
Adia Med's Days Sales Outstanding
declined
from Dec. 2025 (402.66) to Jun. 2026 (46.28).
Adia Med (OTCPK:ADIA) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Adia Med Days Sales Outstanding Related Terms
Adia Med Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Adia Med's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADIA vs SYRA, GBCS, AMS: Days Sales Outstanding Comparison
For the Medical Care Facilities subindustry, Adia Med's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adia Med Days Sales Outstanding vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Adia Med's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Adia Med's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adia Med (ADIA) has a Days Sales Outstanding of 46.28 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Adia Med and its competitors. This is 169% above median its historical median of 17.18. Over the past decade, Adia Med's Days Sales Outstanding has ranged from 17.18 to 17.71. According to the industry distribution chart, Adia Med ranks #105 out of 664 companies in the Healthcare Providers & Services industry, placing it in the top 15.8%.
Is Adia Med's Days Sales Outstanding too high?
Adia Med's current Days Sales Outstanding of 46.28 is 169% above median its 10-year median of 17.18. Over the past 10 years, this metric has ranged from a low of 17.18 to a high of 17.71. The Healthcare Providers & Services industry median Days Sales Outstanding is 45.78. Adia Med's value of 46.28 is 1.1% above this industry median. Based on the distribution chart, Adia Med ranks #105 out of 664 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Adia Med has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Adia Med's Days Sales Outstanding compare to SYRA and GBCS?
According to the Healthcare Providers & Services industry distribution chart, Adia Med ranks #105 out of 664 companies for Days Sales Outstanding. This places Adia Med in the top 16% of its industry — outperforming the majority of peers. The industry median Days Sales Outstanding is 45.78. Adia Med's value of 46.28 is 1.1% above this benchmark. Historically, Adia Med's own Days Sales Outstanding has ranged from 17.18 to 17.71 over the past decade. While the company's 10-year median is 17.18 vs. the industry median of 45.78, Adia Med has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Healthcare Providers & Services company?
The median Days Sales Outstanding among Healthcare Providers & Services companies is 45.78, based on 664 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Adia Med's current Days Sales Outstanding of 46.28 is 1.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Adia Med and its competitors. For the Healthcare Providers & Services industry, the median Days Sales Outstanding is 45.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adia Med's current Days Sales Outstanding is 46.28, which is 169% above median its own 10-year median of 17.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adia Med stock overvalued right now?
Adia Med (ADIA) has a current Days Sales Outstanding of 46.28. The current Days Sales Outstanding is 46.28, which is 169% above median its 10-year median of 17.18 and 1.1% above the Healthcare Providers & Services industry median of 45.78. Adia Med's overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Adia Med (ADIA), the current Days Sales Outstanding is 46.28 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Adia Nutrition Inc focus is to work closely with healthcare providers and health insurance companies to facilitate and provide Autologous Hematopoietic Stem Cell Transplantation (AHSCT). Its products and the deployment of the therapies utilizing its products address various orthopedic issues, pain management, and wound repair. In addition, its products are able to be utilized in various other therapies to address anti-aging issues and other tissue repair desires. It operates in three segments The Biolete segment comprises the sale of supplements; Adia Med performs stem cell treatments to patients; and Adia Labs procures and sells stem cell products to outside clinics or to Adia Med. It derives revenue from Sales of supplements, Medical procedures, Sales of biologics and ancillary products.
20GF Score
Get the complete analysis for ADIA
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADIA has been successfully added to your 
